EvolvE | EoE | About the Study

What is the EvolvE study?

The EvolvE study is a clinical research study for adults with eosinophilic esophagitis (EoE). This EoE study is designed to find out whether the study drug, barzolvolimab (CDX-0159), can be a potential treatment for EoE without causing too many side effects.

Learn more about barzolvolimab

Who can join the EvolvE study?

You may be able to join the study if you meet the following requirements:

At least 18 years old
Diagnosed with EoE and have experienced difficulty swallowing solid foods
Have not significantly changed your diet in the last 2 months
For example, you have not started eliminating food groups to identify EoE triggers, and you have not started reintroducing previously eliminated food groups
Have tried standard-of-care EoE treatment without improvement or were not able to use standard-of-care treatment
Standard-of-care treatment includes proton pump inhibitors (PPIs), swallowed topical corticosteroids, and dietary elimination

Other study requirements will apply.

See if you may qualify

What can study participants expect?

The study lasts about 46 weeks (a little more than 10 months), divided into the following periods:

Screening Period
(up to 6 weeks)

Have study assessments to find out if you can join the study
Start recording information in an electronic study diary that you will use throughout the study

Medication Period
(28 weeks)*

Receive 2 injections every 8 weeks (for about 6 months)
Attend study visits every 2 to 4 weeks and continue recording in the electronic study diary

Follow-up Period
(16 weeks)

Attend follow-up study visits every 4 weeks and continue recording in the electronic study diary

*Note: All patients will receive active drug during the study. Some patients may be randomly assigned to receive placebo for approximately 4 months.

Participation in a clinical study is voluntary. You can ask any questions you have and may leave the study at any time, for any reason.

EvolvE Study

What is the EvolvE study?

Who can join the EvolvE study?

What can study participants expect?

Screening Period(up to 6 weeks)

Medication Period (28 weeks)*

Follow-up Period(16 weeks)

Screening Period
(up to 6 weeks)

Medication Period
(28 weeks)*

Follow-up Period
(16 weeks)